Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1870871 | 0.98 | TDP1 (0.48) | TDP1MAPTTSHRMAPK1LMNA | |
| SCHEMBL10713829 | 0.83 | TDP1 (0.47) | TDP1MAPTTSHRMAPK1LMNA | |
| SCHEMBL1534154 | 0.83 | TDP1 (0.47) | TDP1MAPTTSHRMAPK1HSD17B10 | |
| SCHEMBL28396141 | 0.83 | TSHR (0.32) | TDP1TSHR | |
| SCHEMBL536926 | 0.83 | TDP1 (0.47) | TDP1MAPTTSHRMAPK1HSD17B10 | |
| SCHEMBL320016 | 0.82 | — | — | |
| SCHEMBL1498062 | 0.81 | TDP1 (0.42) | TDP1MAPTTSHR | |
| SCHEMBL36446 | 0.81 | TDP1 (0.48) | TDP1MAPTTSHRMAPK1LMNA | |
| SCHEMBL536618 | 0.81 | TDP1 (0.48) | TDP1MAPTTSHRMAPK1HSD17B10 | |
| Methoxymethane SCHEMBL3383278 | 0.80 | TDP1 (0.44) | TDP1MAPTTSHRMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080038316-A1 | Conveniently implantable sustained release drug compositions | RAMSCOR, INC. | 2008-02-14 | — | — | US | claimed |
| EP-3173072-A1 | CONVENIENTLY IMPLANTABLE SUSTAINED RELEASE DRUG COMPOSITIONS | Ramscor, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9289428-B2 | Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer | RAMSCOR, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150273066-A1 | CONVENIENTLY IMPLANTABLE SUSTAINED RELEASE DRUG COMPOSITIONS | RAMSCOR INC (US) | 2015-10-01 | — | — | US | disclosed |
| US-9011915-B2 | Conveniently implantable sustained release drug compositions | RAMSCOR, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140329785-A1 | Conveniently Injectable or Implantable Sustained-Release Antioxidant Formulations for Therapies of Ocular Maladies or Cancer | RAMSCOR, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| EP-2717866-A2 | CONVENIENTLY INJECTABLE OR IMPLANTABLE SUSTAINED-RELEASE ANTIOXIDANT FORMULATIONS FOR THERAPIES OF OCULAR MALADIES OR CANCER | Ramscor, Inc. (US) | 2014-04-16 | — | — | EP | disclosed |
| WO-2013058838-A2 | CONVENIENTLY INJECTABLE OR IMPLANTABLE SUSTAINED-RELEASE ANTIOXIDANT FORMULATIONS FOR THERAPIES OF OCULAR MALADIES OR CANCER | WONG VERNON G (US) | 2013-04-25 | — | — | WO | disclosed |
| EP-1793803-B1 | CONVENIENTLY IMPLANTABLE SUSTAINED RELEASE DRUG COMPOSITIONS | RAMSCOR INC (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2452670-A1 | Conveniently implantable sustained release drug compositions | Ramscor, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| WO-2006039336-A2 | CONVENIENTLY IMPLANTABLE SUSTAINED RELEASE DRUG COMPOSITIONS | RAMSCOR, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060073182-A1 | Conveniently implantable sustained release drug compositions | RAMSCOR, INC. | 2006-04-06 | — | — | US | disclosed |
| US-6953765-B2 | Double metal cyanide catalysts for preparing polyether polyols | BAYER AKTIENGESELLSCHAFT (DE) | 2005-10-11 | — | — | US | disclosed |
| US-6919293-B1 | Double metal cyanide catalysts for producing polyether polyols | BAYER AKTIENGESELLSCHAFT (DE) | 2005-07-19 | — | — | US | disclosed |
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-02-17 | — | — | US | disclosed |
| US-6852663-B2 | Double-metal cyanide catalysts for preparing polyether polyols | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-08 | — | — | US | disclosed |
| EP-1460062-A1 | NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20030119663-A1 | Double-metal cyanide catalysts for preparing polyether polyols | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-26 | — | — | US | disclosed |
| US-20020198099-A1 | Double metal cyanide catalysts for preparing polyether polyols | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-26 | — | — | US | disclosed |
| US-6323375-B1 | USED AS POLYMERIZATION CATALYST FOR PRODUCING POLYETHERS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | BDKRB1, BDKRB2, TACR1 | TDP1 4086/4885MAPT 4499/4885TSHR 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.